Pharmaceutical and diagnostics company Roche (SIX:RO) (OTCQX:RHHBY) stated on Tuesday that the US FDA EUA Elecsys Anti-SARS-CoV-2 antibody test is being used at more than 20 commercial and hospital lab sites throughout the US.
According to the company, it is working to meet demand by scaling global production rapidly in an effort to expand broader access as quickly as possible. It plans to increase to more than 200 commercial and hospital lab sites with the ability to perform two million tests per week. It has more than 3,000 analyzers that perform the antibody test installed across the US.
The company's Elecsys Anti-SARS-CoV-2 test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. The Elecsys Anti-SARS-CoV-2 assay has 99.8% specificity and shows no cross-reactivity to the common cold, HIV and other coronaviruses. It can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual.
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results